Preparation, characterization, and in vitro release of new transdermal methimazole as alternative to oral delivery

Figures & data

Table 1.  Composition of gel pluronic^® F127.

Formula	Components	Percentage
Gel	Pluronic F-127^®	20
	Methimazole	1
	Distilled water c.s.p. 100 ml

Table 2.  Composition of Pluronic Lecitin Organogel (PLO).

Formula		Components	Percentage
PLO	Oil phase	Soy lecithin	10
		Isopropyl palmitate	10
	Aqueous phase	Methimazole	1
		Gel Pluronic F-127 c.s.p. 100 ml

Figure 1.  Changes in viscosity (cP) of Pluronic^® F-127 gel at 25°C with time.

Figure 2.  Changes in viscosity (cP) of Pluronic^® F-127 gel at 4°C with time.

Figure 3.  Changes in viscosity (cP) of Pluronic lecitin organogel at 4°C with time.

Figure 4.  Changes in viscosity (cP) of Pluronic lecitin organogel at 25°C with time.

Figure 5.  Photomicrograph of Pluronic gel 7 days after preparation.

Figure 6.  Photomicrograph of pluronic lecithin organogel 7 (a), 30 (b), and 90 (c) days after preparation.

Table 3.  Changes in micelle size in Pluronic F127^® gel and in vesicle size in pluronic organogel formulations.

Formula	Gel Pluronic F 127-methimazole
Mean particle size (μm) ± standard deviation
	0.05 ± 0.0065	0.18 ± 0.0063	0.46 ± 0.002	0.52 ± 0.002	0.7 ± 0.0014
Formula	PLO (Pluronic lecitin organogel)-metimazol
	0.035 ± 0.012	0.16 ± 0.07	0.26 ± 0.046	0.8 ± 0.18	0.77±0.15
Time	24 hr	7 days	30 days	60 days	90 days

Figure 7.  Photomicrograph of pluronic gel 1 year after preparation.

Figure 8.  Photomicrograph of pluronic lecithin organogel 1 year after preparation.

Figure 9.  Percentage of drug released from different formulations in release device without membrane.

Figure 10.  Percentage of drug released from different formulations in Franz-type cells.